How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27,537 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

27521. Tazarotene in combination with topical corticosteroids. (PubMed)

Tazarotene in combination with topical corticosteroids. The use of a topical corticosteroid in combination with tazarotene has theoretic appeal because each drug has a different mechanism of action, and it is therefore likely that combination therapy will offer additive or synergistic effects. For example, the steroid may promote a rapid initial response together with minimization of erythema during the treatment period, and tazarotene may prolong the duration of the therapeutic effect (...) and lower the probability of relapse. The results of a large, controlled clinical trial in which corticosteroids of various potencies were added to tazarotene therapy showed that tazarotene plus a medium- or high potency corticosteroid produced greater and more rapid efficacy, and superior tolerability, than tazarotene plus placebo cream.

1998 Journal of the American Academy of Dermatology

27522. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. (PubMed)

Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. We performed a systematic review of randomized, controlled trials to determine whether intranasal corticosteroids offered an advantage over topical antihistamines in the treatment of allergic rhinitis.We searched for studies using MEDLINE, Embase, Cinahi, and Cochrane databases, pharmaceutical companies, and references of included trials.Criteria (...) between studies. Subgroup and sensitivity analysis suggested that most of the heterogeneity of outcomes could be explained on the basis of the methodologic quality of studies.Intranasal corticosteroids produced greater relief of nasal symptoms than did topical antihistamines (topical H1 receptor antagonists). However, there was no difference in the relief of the ocular symptoms.

2002 Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

27523. Sicorten: a synthetic corticosteroid for topical treatment of common dermatoses. (PubMed)

Sicorten: a synthetic corticosteroid for topical treatment of common dermatoses. In an open non-comparative trial 247 eczema patients were treated with Sicorten topicals. Sicorten cream yielded good to very good results in 90%, 97% and 100% of the patients suffering from atopic dermatitis, contact dermatitis and seborrhoeic dermatitis, respectively, while Sicorten ointment produced similar results in 97% and 100% of the patients with chronic atopic dermatitis and chronic contact dermatitis

1986 The Journal of international medical research

27524. A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers. (PubMed)

A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers. Topical glucocorticosteroids are frequently used for the treatment of sunburn despite the scarcity of randomized, double-blind controlled trials to support this indication. This randomized, intra-individually controlled trial compared the efficacy and safety of two topical glucocorticosteroids, 0.1% methylprednisolone aceponate milk (MPA) and 0.1% hydrocortisone 17 (...) were physician's global assessment, individual signs/symptoms, colorimetry, dermatological improvement, and time to healing. Intra-individual comparisons were made. Differences in sum score were apparent on days 3-4 and significant on days 4-5 for corticosteroids compared with nontreatment. Treated areas had significantly lower sunburn reaction than untreated areas (P = 0.1% and P = 0.5% for MPA and HCB, respectively). Differences between treatments were not significant. Secondary efficacy measures

2002 Clinical and experimental dermatology

27525. Comparison of the effects of daily applications between topical corticosteroid and tacrolimus ointments on normal skin: evaluation with noninvasive methods. (PubMed)

Comparison of the effects of daily applications between topical corticosteroid and tacrolimus ointments on normal skin: evaluation with noninvasive methods. To evaluate the skin changes of the neck of normal individuals after repeated applications of moderate-strength corticosteroid or tracrolimus ointment for 3 weeks by use of noninvasive biophysical measurements.A 0.12% betamethasone-17-valerate ointment or a 0.1% tacrolimus ointment was applied to the right side of the neck of 8 adult (...) of the treatment as compared with the petrolatum-treated side. The erythematous reaction to a topically applied 0.1% aqueous solution of methyl nicotinate, a vasodilator, appeared more slowly on the corticosteroid-ointment-treated skin than on the control skin. No such changes were observed on the skin treated with 0.1% tacrolimus ointment.Tacrolimus appears to cause few if any functional changes in the SC of healthy human skin because of its poor permeability into skin with an intact barrier

2002 Dermatology (Basel, Switzerland)

27526. Efficacy of topical corticosteroids in nickel-induced contact allergy. (PubMed)

Efficacy of topical corticosteroids in nickel-induced contact allergy. In this study we used the nickel contact allergy patch (CAP) test to investigate the effect of topical corticosteroids on allergic contact dermatitis (ACD). On day 1, three CAP tests were applied for 48 h on the forearms of 20 female volunteers with a known nickel ACD. CAP of the right forearm contained 5% nickel, and of the left forearm physiological saline. Clinical scoring, transepidermal water loss and skin hydration (...) were measured on day 1 before CAP application, on day 4 (0, 2 and 6 h) after ACD and from days 5 to 8 (0 h). A topical corticosteroid and its vehicle were applied twice daily starting from day 4 on two ACD sites. Transepidermal water loss values were significantly decreased on the topical-corticosteroid-treated sites in the early phase of ACD (day 4, 6 h after the first application) while clinical efficacy showed significant improvement on days 7 and 8. The vehicle was found to improve skin

2002 Clinical and experimental dermatology

27527. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. (PubMed)

Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Radiation dermatitis is a common side-effect of radiation therapy, but there is no current consensus about its appropriate therapy.To compare treatment with topical 0.1% methylprednisolone vs. 0.5% dexpanthenol in a cohort of patients undergoing fractionated radiation therapy for breast cancer.In a randomized, double-blind design, treatment was initiated at the beginning of radiation (...) of radiation dermatitis, both delayed the emergence of greatest clinical and TEWL scores until approximately 6 and 5 weeks, respectively. With topical corticosteroids, clinical symptoms and TEWL were less pronounced than with dexpanthenol. Whereas general QOL improved after completion of radiation therapy, skin-related QOL declined. However, the skin-related QOL decline could be at least in part reversed by use of topical corticosteroid vs. dexpanthenol-containing emollient.We provide evidence

2002 The British journal of dermatology

27528. [Treatment with topical corticosteroids in severe or resistant dermatoses]. (PubMed)

[Treatment with topical corticosteroids in severe or resistant dermatoses]. The efficacy and safety of betamethasone dipropionate glycol cream 0.05% and desoximetasone ointment 0.25% were compared in a randomized, double-blind study of 80 patients with resistant or severe corticosteroid-responsive dermatoses. Medication was applied to affected areas at a dosage of 3.5 grams twice daily for 14 days. In each treatment group, evaluation of efficacy was based on results in 35 patients

1985 Dermatosen in Beruf und Umwelt. Occupation and environment

27529. Comparative merits of two topical corticosteroid antimicrobial drugs. (PubMed)

Comparative merits of two topical corticosteroid antimicrobial drugs. The anti-inflammatory and antimicrobial activities of two topical creams, one containing halcinonide, neomycin and nystatin (HNN), and the other betamethasone valerate, gentamicin, iodochlorhydroxyquin and tolnaftate (BGI), were compared in a randomized, parallel study of 154 patients (eighty-seven secondarily infected eczematous dermatoses; sixty-seven cutaneous candidiasis). Repeated clinical assessments showed that the two

1981 The Journal of international medical research

27530. Halogenation and topical corticosteroids: a comparison between the 17-butyrate esters of hydrocortisone and clobetasone in ointment bases. (PubMed)

Halogenation and topical corticosteroids: a comparison between the 17-butyrate esters of hydrocortisone and clobetasone in ointment bases. Clobetasone butyrate 0.05% (Eumovate), a halogenated topical steroid, was compared with hydrocortison butyrate 0.1% (Locoid) which does not contain any halogen atoms. In the treatment of eczema there was not difference between the preparations, but in that of psoriasis the halogen-containing steriod was significantly more effective. Under normal (...) circumstances neither preparation had any detectable effect on adrenal function, but with large doses under total-body polythene occlusion, circulating cortisol levels were reduced less by the halogenated than by the non-halogenated preparation. Corticosteroids which contain a halogen atom are often considered to cause more adverse effects than the non-halogenated preparations with similar clinical efficacy. This study shows that this cannot be assumed for their ability to suppress cortisol levels.

1981 The British journal of dermatology

27531. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. (PubMed)

Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days). Each patient received, in a double-masked, randomized manner, either 1% prednisolone phosphate or placebo eyedrops in each eye 12 hours before and along with the cytarabine so (...) that we could determine whether a topical corticosteroid prevents corneal toxicity from systemic cytarabine. Ten of the 11 patients had a significant reduction in the intensity and duration of the symptoms and signs of corneal toxicity in the corticosteroid-treated eye (P less than .0005). In the placebo-treated eye, pain, photophobia, and tearing occurred at a median time of 6.5 days after initiation of therapy but resolved in approximately one week. Patients receiving high doses of intravenously

1982 American journal of ophthalmology

27532. Short-term topical corticosteroid therapy (halcinonide ointment) in the management of atopic dermatitis. (PubMed)

Short-term topical corticosteroid therapy (halcinonide ointment) in the management of atopic dermatitis. The efficacy of short-term treatment of acute exacerbations of atopic dermatitis with a corticosteroid ointment (halcinonide, 0.1 percent) was demonstrated by comparing such a formulation with its ointment base (placebo). A double-blind, paired comparison study was conducted in 214 patients. Within two weeks the therapeutic response was judged excellent in 137 (64 percent) of the patients (...) receiving the corticosteroid treatment. The number of responses judged good to excellent was 182 (85 percent). With the placebo, there was an excellent response in 50 (23 percent) of the patients and the number judged good to excellent was 95 (44 percent). Although these placebo responses attested to the appropriateness of a highly occlusive ointment vehicle in this condition, the corticosteroid containing formulation was superior (p less than 0.001). In only 10 (5 percent) of the patients

1982 Cutis; cutaneous medicine for the practitioner

27533. A randomized trial of topical corticosteroids in epithelial healing after keratoplasty. (PubMed)

A randomized trial of topical corticosteroids in epithelial healing after keratoplasty. A prospective randomized trial evaluating the effect of topical 1% prednisolone acetate on epithelial defects after keratoplasty in 39 patients (18 in the untreated group and 21 in the treated group) failed to reveal any significant differences in healing between the two groups (p less than 0.16 to p less than 0.54 on post-operative days 1-5). The mean time needed for complete healing was 1.94 days (...) in the untreated group and 2.81 days in the steroid treated group (p less than 0.09). Patients given subconjunctival methylprednisolone sodium succinate had larger initial defects (mean 33.5 mm2) than those not given subconjunctival steroids (mean 16.1 mm2), but the time for complete epithelial healing did not differ significantly (2.75 days vs. 1.91 days; p less than 0.14). As clinically used post-keratoplasty topical steroids do not appear to significantly delay epithelial healing in most patients.

1987 Cornea

27534. A study of potential skin atrophy following topical application of weak corticosteroids. (PubMed)

A study of potential skin atrophy following topical application of weak corticosteroids. A double-blind, half-side comparative dermal atrophy study of fluocortin butylester 0.75% clobetasone butyrate 0.05%, hydrocortisone acetate 1% and placebo creams was carried out in 29 healthy human male volunteers. Skin thickness was measured by a modified radiographic technique before and after an 8-week application period of the test preparations. Significant skin thinning occurred in 3 of the 10 (...) subjects treated with clobetasone butyrate and atrophy of marginal significance in 1 of the 29 subjects treated with fluocortin butylester. The results suggest that, compared with other fluorinated topical steroids, fluocortin butylester 0.75% is unlikely to produce significant dermal atrophy when used in the short and medium term.

1981 Current medical research and opinion

27535. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. (PubMed)

Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. Both the pattern of mediator release during the late-phase response (LPR) and the reduction of the LPR with corticosteroid pretreatment have suggested that basophils, not mast cells, represent the main source of histamine in the late response to nasal antigen challenge. We tested this hypothesis by examining alcian blue-stained cytospin slides of nasal washings obtained before and for 11 hours (...) after nasal antigen challenge in 11 asymptomatic subjects with seasonal allergic rhinitis. In a double-blind manner, subjects received placebo or topical flunisolide (50 micrograms, each nostril, twice daily) for 1 week before antigen challenge. One month later, the challenge was repeated with the alternate pretreatment. On placebo-treatment days, a twelve-fold increase occurred in the number and a threefold increase in the percentage of alcian blue-stained positive cells in nasal washings

1988 The Journal of allergy and clinical immunology

27536. Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays. A comparative randomized trial. (PubMed)

Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays. A comparative randomized trial. To investigate the effect of Grenz ray therapy alone compared with Grenz rays combined with a topical corticosteroid (betamethasone dipropionate) in psoriasis of the scalp, 40 patients were randomized into two groups. One group received 4 Gy of Grenz rays administered on six occasions at intervals of 1 week and the other group was given the same Grenz ray treatment (...) plus topical corticosteroid. The patients were assessed before and after Grenz ray therapy and were followed-up for 6 months. Of the 37 patients who completed the trial 16 out of 19 (84%) of the patients in the Grenz ray group, and 13 out of 18 (72%) of the patients in the combination group healed. The remission time did not differ significantly between the two groups. Of the patients who healed, 5 of 16 patients in the Grenz ray only group and 4 of 13 patients in the combination group remained

1988 The British journal of dermatology

27537. The effect of topical corticosteroids on Ki67 and p53 expression in vulval lichen sclerosus. (PubMed)

The effect of topical corticosteroids on Ki67 and p53 expression in vulval lichen sclerosus. Topical corticosteroids have become the treatment of choice for genital lichen sclerosus (LS) and are believed to be required for long-term relief of symptoms.To compare vulval LS that had been treated with topical corticosteroids, vulval LS that had not received topical corticosteroids, and histologically normal vulval skin.We used immunohistochemistry to look for Ki67 expression and abnormal p53 (...) expression.We found a statistically significant difference for p53 overexpression, with increased levels seen when comparing corticosteroid-treated LS with normal genital skin (P = 0.011). Ki67 expression was also significantly higher in the corticosteroid-treated group compared with normal genital skin (P = 0.001), and increased levels were also found in the treated group compared with untreated LS (P = 0.05).Our data suggest that topical corticosteroids have an effect on cell cycle proteins in genital

2002 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>